イリノイ州における強皮症の臨床試験
イリノイ州内の拠点で、強皮症に関する11件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- University of Illinois Health Outpatient Care Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06655155A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/10更新 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
被験者募集中第2/3相
18歳〜75歳 · 全性別 · 2026/08/17更新 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/08/07更新 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07295847Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2025/05/07更新 · NCT05892614ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。